Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$42.56 USD
+0.06 (0.14%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $42.59 +0.03 (0.07%) 7:00 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 261 - 280 ( 286 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PEGASUS Makes EHA Debut; Regulatory Filings Next Step
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pegcetacoplan Filing On Track For 2H20 After FDA Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Additional Note Offering Necessary To Extend Cash Runway
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady As She Goes; Largely Uneventful 1Q20 Report Ahead Of Mid-Year Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upgrade to Neutral; Despite Some Data Questions, Valuation Warrants Revisiting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ahead of Detailed Data, FDA Feedback - Uneventful 4Q19 EPS Report
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L